Trung Huynh
Stock Analyst at UBS
(1.91)
# 1335
Out of 5,243 analysts
30
Total ratings
60.00%
Success rate
24.61%
Average return
Main Sectors:
Top Industries:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Kyverna Therapeutics | Initiates Coverage On: Buy | 13 | 3.29 | 295.14% | 1 | Oct 10, 2024 | |
Cabaletta Bio | Initiates Coverage On: Buy | 10 | 2.21 | 352.49% | 1 | Oct 10, 2024 | |
Bristol-Myers Squibb | Maintains: Neutral | 50 54 | 55.98 | -3.54% | 4 | Oct 9, 2024 | |
Insmed | Maintains: Strong Buy | 78 84 | 70.19 | 19.68% | 3 | Aug 9, 2024 | |
Eli Lilly | Assumes: Strong Buy | 612 710 | 746.46 | -4.88% | 7 | Oct 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 170 175 | 144.71 | 20.93% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 220 200 | 269.05 | -25.66% | 3 | Jul 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 47 40 | 26.25 | 52.38% | 4 | Jun 29, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Outperform | 125 126 | 100.2 | 25.75% | 3 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Outperform | 170 | 171.35 | -0.79% | 1 | Nov 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Outperform | n/a | n/a | n/a | 1 | Mar 23, 2021 |